{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:18:07Z","timestamp":1793744287326,"version":"4.6.1"},"reference-count":275,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41571-026-01141-2","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:01:04Z","timestamp":1776160864000},"page":"481-500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-8160","authenticated-orcid":false,"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"1141_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury, J. D. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36, 1703\u20131719 (2022).","journal-title":"Leukemia"},{"key":"1141_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber, D. A. et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: integrating morphological, clinical, and genomic data. Blood 140, 1200\u20131228 (2022).","journal-title":"Blood"},{"key":"1141_CR3","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola, M. Myelodysplastic syndromes. N. Engl. J. Med. 383, 1358\u20131374 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/blood-2023-186863","volume":"142","author":"E Bernard","year":"2023","unstructured":"Bernard, E. et al. Molecular taxonomy of myelodysplastic syndromes and its clinical implications. Blood 142, 997\u2013997 (2023).","journal-title":"Blood"},{"key":"1141_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241\u2013247 (2014).","journal-title":"Leukemia"},{"key":"1141_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood.V126.23.907.907","volume":"126","author":"R Bejar","year":"2015","unstructured":"Bejar, R. et al. Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood 126, 907 (2015).","journal-title":"Blood"},{"key":"1141_CR7","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496\u20132506 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR8","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard, E. et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid. 1, EVIDoa2200008 (2022).","journal-title":"NEJM Evid."},{"key":"1141_CR9","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.20.02810","volume":"39","author":"A Nazha","year":"2021","unstructured":"Nazha, A. et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J. Clin. Oncol. 39, 3737\u20133746 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR10","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.20.01659","volume":"39","author":"M Bersanelli","year":"2021","unstructured":"Bersanelli, M. et al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J. Clin. Oncol. 39, 1223\u20131233 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR11","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1200\/JCO.23.02175","volume":"42","author":"CA Tentori","year":"2024","unstructured":"Tentori, C. A. et al. Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes. J. Clin. Oncol. 42, 2873\u20132886 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1053\/j.seminhematol.2024.09.005","volume":"61","author":"JJ Rodriguez-Sevilla","year":"2024","unstructured":"Rodriguez-Sevilla, J. J. & Colla, S. Inflammation in myelodysplastic syndrome pathogenesis. Semin. Hematol. 61, 385\u2013396 (2024).","journal-title":"Semin. Hematol."},{"key":"1141_CR13","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1200\/JCO.19.01823","volume":"38","author":"S Winter","year":"2020","unstructured":"Winter, S., Shoaie, S., Kordasti, S. & Platzbecker, U. Integrating the \u201cimmunome\u201d in the stratification of myelodysplastic syndromes and future clinical trial design. J. Clin. Oncol. 38, 1723\u20131735 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","volume":"34","author":"AM Zeidan","year":"2019","unstructured":"Zeidan, A. M., Shallis, R. M., Wang, R., Davidoff, A. & Ma, X. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 34, 1\u201315 (2019).","journal-title":"Blood Rev."},{"key":"1141_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1414799","volume":"373","author":"T Yoshizato","year":"2015","unstructured":"Yoshizato, T. et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N. Engl. J. Med. 373, 35\u201347 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-022-00402-5","volume":"8","author":"H Li","year":"2022","unstructured":"Li, H., Hu, F., Gale, R. P., Sekeres, M. A. & Liang, Y. Myelodysplastic syndromes. Nat. Rev. Dis. Primers 8, 74 (2022).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1141_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood.2019000940","volume":"136","author":"L Sun","year":"2020","unstructured":"Sun, L. & Babushok, D. V. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood 136, 36\u201349 (2020).","journal-title":"Blood"},{"key":"1141_CR18","doi-asserted-by":"publisher","unstructured":"Weeks, L. D. et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid. https:\/\/doi.org\/10.1056\/evidoa2200310 (2023).","DOI":"10.1056\/evidoa2200310"},{"key":"1141_CR19","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.3390\/cancers16234118","volume":"16","author":"Q Zhang","year":"2024","unstructured":"Zhang, Q. et al. Implications of clonal hematopoiesis in hematological and non-hematological disorders. Cancers 16, 4118 (2024).","journal-title":"Cancers"},{"key":"1141_CR20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux, P. et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N. Engl. J. Med. 382, 140\u2013151 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux, P. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10, 223\u2013232 (2009).","journal-title":"Lancet Oncol."},{"key":"1141_CR22","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian, H. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106, 1794\u20131803 (2006).","journal-title":"Cancer"},{"key":"1141_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","volume":"403","author":"U Platzbecker","year":"2024","unstructured":"Platzbecker, U. et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 403, 249\u2013260 (2024).","journal-title":"Lancet"},{"key":"1141_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","volume":"402","author":"U Platzbecker","year":"2023","unstructured":"Platzbecker, U. et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet 402, 373\u2013385 (2023).","journal-title":"Lancet"},{"key":"1141_CR25","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1200\/JCO.22.02699","volume":"41","author":"EN Oliva","year":"2023","unstructured":"Oliva, E. N. et al. Eltrombopag for low-risk myelodysplastic syndromes with thrombocytopenia: interim results of a phase II, randomized, placebo-controlled clinical trial (EQOL-MDS). J. Clin. Oncol. 41, 4486\u20134496 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR26","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(24)00476-8","volume":"403","author":"AE Schumacher","year":"2024","unstructured":"Schumacher, A. E. et al. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950\u20132021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet 403, 1989\u20132056 (2024).","journal-title":"Lancet"},{"key":"1141_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1559382","volume":"15","author":"X Gou","year":"2025","unstructured":"Gou, X., Chen, Z. & Shangguan, Y. Global, regional, and national burden of myelodysplastic syndromes and myeloproliferative neoplasms, 1990-2021: an analysis from the global burden of disease study 2021. Front. Oncol. 15, 1559382 (2025).","journal-title":"Front. Oncol."},{"key":"1141_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.leukres.2013.10.023","volume":"38","author":"CR Cogle","year":"2014","unstructured":"Cogle, C. R. et al. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk. Res. 38, 71\u201375 (2014).","journal-title":"Leuk. Res."},{"key":"1141_CR29","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1002\/cncr.28641","volume":"120","author":"ZK McQuilten","year":"2014","unstructured":"McQuilten, Z. K. et al. Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study. Cancer 120, 1686\u20131694 (2014).","journal-title":"Cancer"},{"key":"1141_CR30","first-page":"168","volume":"48","author":"A Shrestha","year":"2021","unstructured":"Shrestha, A., Stewart, E. & Cress, R. Are we undercounting MDS? An analysis of incidence patterns of myelodysplastic syndromes in SEER 21 regions: 2001\u20132016. J. Registry Manag. 48, 168\u2013173 (2021).","journal-title":"J. Registry Manag."},{"key":"1141_CR31","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1097\/PAS.0000000000000749","volume":"40","author":"MA Duggan","year":"2016","unstructured":"Duggan, M. A., Anderson, W. F., Altekruse, S., Penberthy, L. & Sherman, M. E. The Surveillance, Epidemiology, and End Results (SEER) program and pathology: toward strengthening the critical relationship. Am. J. Surg. Pathol. 40, e94\u2013e102 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"1141_CR32","unstructured":"National Cancer Institute. Myelodysplastic syndromes (MDS). SEER*Explorer https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=409&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on#resultsRegion0 (2024)."},{"key":"1141_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107056","volume":"128","author":"TB Lauritsen","year":"2023","unstructured":"Lauritsen, T. B. et al. 10-year nationwide trends in incidence, treatment patterns, and mortality of patients with myelodysplastic syndromes in Denmark. Leuk. Res. 128, 107056 (2023).","journal-title":"Leuk. Res."},{"key":"1141_CR34","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/j.1445-5994.2011.02619.x","volume":"42","author":"EJ Rodger","year":"2012","unstructured":"Rodger, E. J. & Morison, I. M. Myelodysplastic syndrome in New Zealand and Australia. Intern. Med. J. 42, 1235\u20131242 (2012).","journal-title":"Intern. Med. J."},{"key":"1141_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","volume":"42","author":"E Roman","year":"2016","unstructured":"Roman, E. et al. Myeloid malignancies in the real-world: occurrence, progression and survival in the UK\u2019s population-based Haematological Malignancy Research Network 2004-15. Cancer Epidemiol. 42, 186\u2013198 (2016).","journal-title":"Cancer Epidemiol."},{"key":"1141_CR36","doi-asserted-by":"publisher","unstructured":"Bekadja, M. F. P. et al. Adults myelodysplastic syndromes in Algeria: a study by the Algerian MDS Group. Asian Pac. J. Cancer Biol. https:\/\/doi.org\/10.31557\/apjcb.2023.8.1.21-29 (2023).","DOI":"10.31557\/apjcb.2023.8.1.21-29"},{"key":"1141_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2188\/jea.JE20140042","volume":"24","author":"D Chihara","year":"2014","unstructured":"Chihara, D. et al. Incidence of myelodysplastic syndrome in Japan. J. Epidemiol. 24, 469\u2013473 (2014).","journal-title":"J. Epidemiol."},{"key":"1141_CR38","unstructured":"International Agency for Research on Cancer. CI5 XII \u2013 Cancer Incidence in 5 Continents. Volume XII https:\/\/ci5.iarc.fr\/ci5-xii\/ (2025)."},{"key":"1141_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5045\/br.2015.50.4.204","volume":"50","author":"EH Park","year":"2015","unstructured":"Park, E. H. et al. Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012. Blood Res. 50, 204\u2013217 (2015).","journal-title":"Blood Res."},{"key":"1141_CR40","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/jnci\/djs411","volume":"104","author":"AR Schnatter","year":"2012","unstructured":"Schnatter, A. R., Glass, D. C., Tang, G., Irons, R. D. & Rushton, L. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J. Natl Cancer Inst. 104, 1724\u20131737 (2012).","journal-title":"J. Natl Cancer Inst."},{"key":"1141_CR41","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1046\/j.1365-2141.2001.02645.x","volume":"112","author":"C Nisse","year":"2001","unstructured":"Nisse, C. et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. Br. J. Haematol. 112, 927\u2013935 (2001).","journal-title":"Br. J. Haematol."},{"key":"1141_CR42","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(17)30832-X","volume":"18","author":"D Loomis","year":"2017","unstructured":"Loomis, D. et al. Carcinogenicity of benzene. Lancet Oncol. 18, 1574\u20131575 (2017).","journal-title":"Lancet Oncol."},{"key":"1141_CR43","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/JOM.0000000000000952","volume":"59","author":"GB Copley","year":"2017","unstructured":"Copley, G. B. et al. Hospital-based case-control study of MDS subtypes and benzene exposure in Shanghai. J. Occup. Env. Med. 59, 349\u2013355 (2017).","journal-title":"J. Occup. Env. Med."},{"key":"1141_CR44","volume":"5","author":"N Anwar","year":"2022","unstructured":"Anwar, N. et al. Environmental and occupational determinants of myelodysplastic syndrome: a case-control study from Pakistan. Cancer Rep. 5, e1580 (2022).","journal-title":"Cancer Rep."},{"key":"1141_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ajh.21941","volume":"86","author":"L Lv","year":"2011","unstructured":"Lv, L. et al. Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population. Am. J. Hematol. 86, 163\u2013169 (2011).","journal-title":"Am. J. Hematol."},{"key":"1141_CR46","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/10245332.2016.1277006","volume":"22","author":"C Avgerinou","year":"2017","unstructured":"Avgerinou, C. et al. Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece. Hematology 22, 419\u2013429 (2017).","journal-title":"Hematology"},{"key":"1141_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/00001648-200005000-00010","volume":"11","author":"J Bj\u00f6rk","year":"2000","unstructured":"Bj\u00f6rk, J. et al. Smoking and myelodysplastic syndromes. Epidemiology 11, 285\u2013291 (2000).","journal-title":"Epidemiology"},{"key":"1141_CR48","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/bjh.14749","volume":"178","author":"T Ugai","year":"2017","unstructured":"Ugai, T. et al. Smoking and alcohol and subsequent risk of myelodysplastic syndromes in Japan: the Japan Public Health Centre-based Prospective Study. Br. J. Haematol. 178, 747\u2013755 (2017).","journal-title":"Br. J. Haematol."},{"key":"1141_CR49","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/aje\/kwp074","volume":"169","author":"X Ma","year":"2009","unstructured":"Ma, X. et al. Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. Am. J. Epidemiol. 169, 1492\u20131499 (2009).","journal-title":"Am. J. Epidemiol."},{"key":"1141_CR50","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1158\/1055-9965.EPI-19-0106","volume":"28","author":"MR Sweeney","year":"2019","unstructured":"Sweeney, M. R. et al. Medical conditions and modifiable risk factors for myelodysplastic syndrome: a systematic review. Cancer Epidemiol. Biomarkers Prev. 28, 1502\u20131517 (2019).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"1141_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2009.08.006","volume":"34","author":"Y Du","year":"2010","unstructured":"Du, Y., Fryzek, J., Sekeres, M. A. & Taioli, E. Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk. Res. 34, 1\u20135 (2010).","journal-title":"Leuk. Res."},{"key":"1141_CR52","first-page":"241","volume":"32","author":"R Yarosh","year":"2021","unstructured":"Yarosh, R. et al. Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS). Cancer Causes Control. 32, 241\u2013250 (2021).","journal-title":"Cancer Causes Control."},{"key":"1141_CR53","first-page":"623","volume":"22","author":"X Ma","year":"2011","unstructured":"Ma, X. et al. Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. Cancer Causes Control. 22, 623\u2013629 (2011).","journal-title":"Cancer Causes Control."},{"key":"1141_CR54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","volume":"18","author":"K Takahashi","year":"2017","unstructured":"Takahashi, K. et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 18, 100\u2013111 (2017).","journal-title":"Lancet Oncol."},{"key":"1141_CR55","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","volume":"18","author":"NK Gillis","year":"2017","unstructured":"Gillis, N. K. et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 18, 112\u2013121 (2017).","journal-title":"Lancet Oncol."},{"key":"1141_CR56","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Genet. 52, 1219\u20131226 (2020).","journal-title":"Nat. Genet."},{"key":"1141_CR57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180069","volume":"134","author":"K Takahashi","year":"2024","unstructured":"Takahashi, K., Nakada, D. & Goodell, M. Distinct landscape and clinical implications of therapy-related clonal hematopoiesis. J. Clin. Invest. 134, e180069 (2024).","journal-title":"J. Clin. Invest."},{"key":"1141_CR58","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","volume":"21","author":"CC Coombs","year":"2017","unstructured":"Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374\u2013382.e4 (2017).","journal-title":"Cell Stem Cell"},{"key":"1141_CR59","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","volume":"23","author":"JI Hsu","year":"2018","unstructured":"Hsu, J. I. et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell 23, 700\u2013713.e6 (2018).","journal-title":"Cell Stem Cell"},{"key":"1141_CR60","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1001\/jamaoncol.2021.4664","volume":"7","author":"TT Kwan","year":"2021","unstructured":"Kwan, T. T. et al. Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with rucaparib. JAMA Oncol. 7, 1772\u20131781 (2021).","journal-title":"JAMA Oncol."},{"key":"1141_CR61","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong, T. N. et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518, 552\u2013555 (2015).","journal-title":"Nature"},{"key":"1141_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107434","volume":"136","author":"SL Pritzl","year":"2024","unstructured":"Pritzl, S. L. et al. Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate. Leuk. Res. 136, 107434 (2024).","journal-title":"Leuk. Res."},{"key":"1141_CR63","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg, J. R. et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 1752\u20131763 (2021).","journal-title":"Lancet Oncol."},{"key":"1141_CR64","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamaoncol.2020.0078","volume":"6","author":"MB Sonbol","year":"2020","unstructured":"Sonbol, M. B., Halfdanarson, T. R. & Hilal, T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol. 6, 1086\u20131092 (2020).","journal-title":"JAMA Oncol."},{"key":"1141_CR65","first-page":"2187","volume":"110","author":"Y Kusne","year":"2025","unstructured":"Kusne, Y. et al. Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate-specific antigen membrane therapy. Haematologica 110, 2187\u20132192 (2025).","journal-title":"Haematologica"},{"key":"1141_CR66","doi-asserted-by":"publisher","first-page":"pkae116","DOI":"10.1093\/jncics\/pkae116","volume":"9","author":"HJ Lenz","year":"2025","unstructured":"Lenz, H. J. et al. Trilaciclib prior to FOLFOXIRI\/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial. JNCI Cancer Spectr. 9, pkae116 (2025).","journal-title":"JNCI Cancer Spectr."},{"key":"1141_CR67","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","volume":"22","author":"J Weiss","year":"2021","unstructured":"Weiss, J. et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin. Lung Cancer 22, 449\u2013460 (2021).","journal-title":"Clin. Lung Cancer"},{"key":"1141_CR68","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.2217\/fon-2022-0773","volume":"18","author":"S Goel","year":"2022","unstructured":"Goel, S. et al. Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. Future Oncol. 18, 3701\u20133711 (2022).","journal-title":"Future Oncol."},{"key":"1141_CR69","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2025-4","volume":"146","author":"I Chan","year":"2025","unstructured":"Chan, I. et al. CDK4\/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis. Blood 146, 4 (2025).","journal-title":"Blood"},{"key":"1141_CR70","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1200\/JCO.2010.31.3080","volume":"29","author":"M Iwanaga","year":"2011","unstructured":"Iwanaga, M. et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J. Clin. Oncol. 29, 428\u2013434 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR71","doi-asserted-by":"publisher","first-page":"i88","DOI":"10.1093\/jrr\/rrae003","volume":"65","author":"K Ando","year":"2024","unstructured":"Ando, K. & Miyazaki, Y. Myelodysplastic syndromes among atomic bomb survivors in Nagasaki: similarities to and differences from de novo and therapy-related cases. J. Radiat. Res. 65, i88\u2013i96 (2024).","journal-title":"J. Radiat. Res."},{"key":"1141_CR72","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3324\/haematol.2019.219386","volume":"105","author":"M Taguchi","year":"2020","unstructured":"Taguchi, M. et al. Genome analysis of myelodysplastic syndromes among atomic bomb survivors in Nagasaki. Haematologica 105, 358\u2013365 (2020).","journal-title":"Haematologica"},{"key":"1141_CR73","first-page":"1974","volume":"110","author":"L Kotmayer","year":"2025","unstructured":"Kotmayer, L., Kennedy, A. L. & Wlodarski, M. W. Germline and somatic genetic landscape of pediatric myelodysplastic syndromes. Haematologica 110, 1974\u20131986 (2025).","journal-title":"Haematologica"},{"key":"1141_CR74","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41568-020-00315-z","volume":"21","author":"JM Klco","year":"2021","unstructured":"Klco, J. M. & Mullighan, C. G. Advances in germline predisposition to acute leukaemias and myeloid neoplasms. Nat. Rev. Cancer 21, 122\u2013137 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1141_CR75","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/leu.2016.342","volume":"31","author":"V Pastor","year":"2017","unstructured":"Pastor, V. et al. Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants. Leukemia 31, 759\u2013762 (2017).","journal-title":"Leukemia"},{"key":"1141_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01590-5","volume":"8","author":"JR Schwartz","year":"2017","unstructured":"Schwartz, J. R. et al. The genomic landscape of pediatric myelodysplastic syndromes. Nat. Commun. 8, 1557 (2017).","journal-title":"Nat. Commun."},{"key":"1141_CR77","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1046\/j.1365-2141.2003.04361.x","volume":"121","author":"SJ Passmore","year":"2003","unstructured":"Passmore, S. J. et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br. J. Haematol. 121, 758\u2013767 (2003).","journal-title":"Br. J. Haematol."},{"key":"1141_CR78","first-page":"1569","volume":"9","author":"H Hasle","year":"1995","unstructured":"Hasle, H., Kerndrup, G. & Jacobsen, B. B. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia 9, 1569\u20131572 (1995).","journal-title":"Leukemia"},{"key":"1141_CR79","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1182\/blood.2022015790","volume":"140","author":"S Feurstein","year":"2022","unstructured":"Feurstein, S. et al. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood 140, 2533\u20132548 (2022).","journal-title":"Blood"},{"key":"1141_CR80","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432218","volume":"44","author":"LA Godley","year":"2024","unstructured":"Godley, L. A., DiNardo, C. D. & Bolton, K. Germline predisposition in hematologic malignancies: testing, management, and implications. Am. Soc. Clin. Oncol. Educ. Book 44, e432218 (2024).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1141_CR81","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/bjh.18682","volume":"201","author":"A Clark","year":"2023","unstructured":"Clark, A. et al. Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT). Br. J. Haematol. 201, 35\u201344 (2023).","journal-title":"Br. J. Haematol."},{"key":"1141_CR82","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood.2023022751","volume":"144","author":"SH Lum","year":"2024","unstructured":"Lum, S. H. et al. Outcomes of hematopoietic stem cell transplantation in 813 pediatric patients with Fanconi anemia. Blood 144, 1329\u20131342 (2024).","journal-title":"Blood"},{"key":"1141_CR83","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines Version 3.2026 - Myelodysplastic Syndrome. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1446 (2026)."},{"key":"1141_CR84","doi-asserted-by":"publisher","first-page":"106","DOI":"10.6004\/jnccn.2022.0009","volume":"20","author":"PL Greenberg","year":"2022","unstructured":"Greenberg, P. L. et al. NCCN Guidelines\u00ae Insights: Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines. J. Natl Compr. Canc Netw. 20, 106\u2013117 (2022).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"1141_CR85","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00518","volume":"8","author":"LG Banaszak","year":"2024","unstructured":"Banaszak, L. G. et al. Implementation of and systems-level barriers to guideline-driven germline genetic evaluation in the care of patients with myelodysplastic syndrome and acute myeloid leukemia. JCO Precis. Oncol. 8, e2300518 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"1141_CR86","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1080\/10428194.2023.2220457","volume":"64","author":"A Hamidi","year":"2023","unstructured":"Hamidi, A. et al. Clinical guideline variability in the diagnosis of hereditary hematopoietic malignancy syndromes. Leuk. Lymphoma 64, 1562\u20131565 (2023).","journal-title":"Leuk. Lymphoma"},{"key":"1141_CR87","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2022018221","volume":"141","author":"H Makishima","year":"2023","unstructured":"Makishima, H. et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood 141, 534\u2013549 (2023).","journal-title":"Blood"},{"key":"1141_CR88","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41375-025-02814-0","volume":"40","author":"C Gurnari","year":"2026","unstructured":"Gurnari, C. et al. DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study. Leukemia 40, 178\u2013187 (2026).","journal-title":"Leukemia"},{"key":"1141_CR89","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat, N. et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients. Am. J. Hematol. 99, 193\u2013202 (2024).","journal-title":"Am. J. Hematol."},{"key":"1141_CR90","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.stem.2021.08.004","volume":"28","author":"TM Chlon","year":"2021","unstructured":"Chlon, T. M. et al. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell 28, 1966\u20131981.e6 (2021).","journal-title":"Cell Stem Cell"},{"key":"1141_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107441","volume":"137","author":"MT Elghetany","year":"2024","unstructured":"Elghetany, M. T., Patnaik, M. M. & Khoury, J. D. Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes \/ germline predisposition syndromes: back under the microscope. Leuk. Res. 137, 107441 (2024).","journal-title":"Leuk. Res."},{"key":"1141_CR92","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/ajcp\/aqad075","volume":"160","author":"N Patel","year":"2023","unstructured":"Patel, N. & Calvo, K. R. How I diagnose myeloid neoplasms with germline predisposition. Am. J. Clin. Pathol. 160, 352\u2013364 (2023).","journal-title":"Am. J. Clin. Pathol."},{"key":"1141_CR93","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.3324\/haematol.2024.285055","volume":"109","author":"O Ceyhan-Birsoy","year":"2024","unstructured":"Ceyhan-Birsoy, O. et al. Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings. Haematologica 109, 3383\u20133390 (2024).","journal-title":"Haematologica"},{"key":"1141_CR94","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.3324\/haematol.2024.285054","volume":"109","author":"M Krystel-Whittemore","year":"2024","unstructured":"Krystel-Whittemore, M. et al. Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies. Haematologica 109, 3269\u20133281 (2024).","journal-title":"Haematologica"},{"key":"1141_CR95","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","volume":"130","author":"F Zink","year":"2017","unstructured":"Zink, F. et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 130, 742\u2013752 (2017).","journal-title":"Blood"},{"key":"1141_CR96","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9\u201316 (2015).","journal-title":"Blood"},{"key":"1141_CR97","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488\u20132498 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR98","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber, D. A. et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200\u20131228 (2022).","journal-title":"Blood"},{"key":"1141_CR99","doi-asserted-by":"publisher","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","volume":"366","author":"S Jaiswal","year":"2019","unstructured":"Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis in human aging and disease. Science 366, eaan4673 (2019).","journal-title":"Science"},{"key":"1141_CR100","first-page":"283","volume":"110","author":"MT Villaume","year":"2025","unstructured":"Villaume, M. T. & Savona, M. R. Pathogenesis and inflammaging in myelodysplastic syndrome. Haematologica 110, 283\u2013299 (2025).","journal-title":"Haematologica"},{"key":"1141_CR101","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-022-04786-y","volume":"606","author":"E Mitchell","year":"2022","unstructured":"Mitchell, E. et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature 606, 343\u2013350 (2022).","journal-title":"Nature"},{"key":"1141_CR102","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","volume":"8","author":"X Li","year":"2023","unstructured":"Li, X. et al. Inflammation and aging: signaling pathways and intervention therapies. Signal. Transduct. Target. Ther. 8, 239 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1141_CR103","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","volume":"129","author":"L Malcovati","year":"2017","unstructured":"Malcovati, L. et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood 129, 3371\u20133378 (2017).","journal-title":"Blood"},{"key":"1141_CR104","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(19)30211-X","volume":"7","author":"LP Gondek","year":"2020","unstructured":"Gondek, L. P. & DeZern, A. E. Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states. Lancet Haematol. 7, e73\u2013e81 (2020).","journal-title":"Lancet Haematol."},{"key":"1141_CR105","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3109\/10428190109097683","volume":"42","author":"S Kimura","year":"2001","unstructured":"Kimura, S. et al. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis-Beh\u00e7et\u2019s syndrome. Leuk. Lymphoma 42, 115\u2013121 (2001).","journal-title":"Leuk. Lymphoma"},{"key":"1141_CR106","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/sj.leu.2400863","volume":"11","author":"M Hebbar","year":"1997","unstructured":"Hebbar, M. et al. Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia 11, 2188\u20132191 (1997).","journal-title":"Leukemia"},{"key":"1141_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000000011","volume":"93","author":"A Mekinian","year":"2014","unstructured":"Mekinian, A. et al. Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases. Medicine 93, 1\u201310 (2014).","journal-title":"Medicine"},{"key":"1141_CR108","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.stem.2018.10.013","volume":"23","author":"Z Cai","year":"2018","unstructured":"Cai, Z. et al. Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell 23, 833\u2013849.e5 (2018).","journal-title":"Cell Stem Cell"},{"key":"1141_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43697-y","volume":"14","author":"J McClatchy","year":"2023","unstructured":"McClatchy, J. et al. Clonal hematopoiesis related TET2 loss-of-function impedes IL1\u03b2-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells. Nat. Commun. 14, 8102 (2023).","journal-title":"Nat. Commun."},{"key":"1141_CR110","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41586-018-0125-z","volume":"557","author":"M Meisel","year":"2018","unstructured":"Meisel, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557, 580\u2013584 (2018).","journal-title":"Nature"},{"key":"1141_CR111","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.stem.2021.03.002","volume":"28","author":"D Hormaechea-Agulla","year":"2021","unstructured":"Hormaechea-Agulla, D. et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN\u03b3 signaling. Cell Stem Cell 28, 1428\u20131442.e6 (2021).","journal-title":"Cell Stem Cell"},{"key":"1141_CR112","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.exphem.2019.11.008","volume":"80","author":"CRC Zhang","year":"2019","unstructured":"Zhang, C. R. C. et al. Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients. Exp. Hematol. 80, 36\u201341.e3 (2019).","journal-title":"Exp. Hematol."},{"key":"1141_CR113","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1126\/science.aba9304","volume":"374","author":"S Avagyan","year":"2021","unstructured":"Avagyan, S. et al. Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. Science 374, 768\u2013772 (2021).","journal-title":"Science"},{"key":"1141_CR114","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1182\/blood-2021-150663","volume":"138","author":"I Ganan-Gomez","year":"2021","unstructured":"Ganan-Gomez, I. et al. The transcriptional and epigenetic reprogramming of aged hematopoietic stem cells drives myeloid rewiring in clonal hematopoiesis-associated cytopenias. Blood 138, 3273 (2021).","journal-title":"Blood"},{"key":"1141_CR115","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ncb3346","volume":"18","author":"EM Pietras","year":"2016","unstructured":"Pietras, E. M. et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat. Cell Biol. 18, 607\u2013618 (2016).","journal-title":"Nat. Cell Biol."},{"key":"1141_CR116","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck, D. B. et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N. Engl. J. Med. 383, 2628\u20132638 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR117","first-page":"3591","volume":"137","author":"PC Grayson","year":"2021","unstructured":"Grayson, P. C., Patel, B. A. & Young, N. S. VEXAS syndrome. Blood 137, 3591\u20133594 (2021).","journal-title":"Blood"},{"key":"1141_CR118","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2022","unstructured":"Georgin-Lavialle, S. et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br. J. Dermatol. 186, 564\u2013574 (2022).","journal-title":"Br. J. Dermatol."},{"key":"1141_CR119","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2023-190210","volume":"142","author":"F Gutierrez-Rodrigues","year":"2023","unstructured":"Gutierrez-Rodrigues, F. et al. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood 142, 244\u2013259 (2023).","journal-title":"Blood"},{"key":"1141_CR120","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s12185-023-03598-8","volume":"118","author":"H Kunimoto","year":"2023","unstructured":"Kunimoto, H. et al. Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome. Int. J. Hematol. 118, 494\u2013502 (2023).","journal-title":"Int. J. Hematol."},{"key":"1141_CR121","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2665-9913(25)00034-7","volume":"7","author":"A Al-Hakim","year":"2025","unstructured":"Al-Hakim, A. et al. Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study. Lancet Rheumatol. 7, e472\u2013e484 (2025).","journal-title":"Lancet Rheumatol."},{"key":"1141_CR122","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood.2022016642","volume":"140","author":"M Heiblig","year":"2022","unstructured":"Heiblig, M. et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood 140, 927\u2013931 (2022).","journal-title":"Blood"},{"key":"1141_CR123","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","volume":"36","author":"A Mekinian","year":"2022","unstructured":"Mekinian, A. et al. A phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML. Leukemia 36, 2739\u20132742 (2022).","journal-title":"Leukemia"},{"key":"1141_CR124","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1182\/blood.2024028133","volume":"146","author":"V Jachiet","year":"2025","unstructured":"Jachiet, V. et al. Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX. Blood 146, 1450\u20131461 (2025).","journal-title":"Blood"},{"key":"1141_CR125","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati, L. et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122, 2943\u20132964 (2013).","journal-title":"Blood"},{"key":"1141_CR126","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett, J. M. et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-operative Group. Br. J. Haematol. 33, 451\u2013458 (1976).","journal-title":"Br. J. Haematol."},{"key":"1141_CR127","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett, J. M. et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51, 189\u2013199 (1982).","journal-title":"Br. J. Haematol."},{"key":"1141_CR128","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-006-0011-x","volume":"1","author":"RS Komrokji","year":"2006","unstructured":"Komrokji, R. S. & Bennett, J. M. Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification. Curr. Hematol. Malig. Rep. 1, 9\u201315 (2006).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"1141_CR129","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"1141_CR130","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937\u2013951 (2009).","journal-title":"Blood"},{"key":"1141_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/genes12081144","volume":"12","author":"C Chiereghin","year":"2021","unstructured":"Chiereghin, C. The genetics of myelodysplastic syndromes: clinical relevance. Genes 12, 1144 (2021).","journal-title":"Genes"},{"key":"1141_CR132","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","volume":"35","author":"A Kuendgen","year":"2021","unstructured":"Kuendgen, A. et al. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification \u2014 an approach to classification of patients with t-MDS. Leukemia 35, 835\u2013849 (2021).","journal-title":"Leukemia"},{"key":"1141_CR133","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1182\/blood-2014-05-574889","volume":"124","author":"AG Kulasekararaj","year":"2014","unstructured":"Kulasekararaj, A. G. et al. Somatic mutations identify a sub-group of aplastic anemia patients that progress to myelodysplastic syndrome. Blood 124, 2698\u20132704 (2014).","journal-title":"Blood"},{"key":"1141_CR134","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood-2018-10-844662","volume":"133","author":"AL Kennedy","year":"2019","unstructured":"Kennedy, A. L. & Shimamura, A. Genetic predisposition to MDS: clinical features and clonal evolution. Blood 133, 1071\u20131085 (2019).","journal-title":"Blood"},{"key":"1141_CR135","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","volume":"29","author":"JR Passweg","year":"2011","unstructured":"Passweg, J. R. et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33\/99. J. Clin. Oncol. 29, 303\u2013309 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR136","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3324\/haematol.2019.219345","volume":"105","author":"M Stahl","year":"2020","unstructured":"Stahl, M., Bewersdorf, J. P., Giri, S., Wang, R. & Zeidan, A. M. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica 105, 102\u2013111 (2020).","journal-title":"Haematologica"},{"key":"1141_CR137","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2002-11-3325","volume":"102","author":"Y Saunthararajah","year":"2003","unstructured":"Saunthararajah, Y., Nakamura, R., Wesley, R., Wang, Q. J. & Barrett, A. J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102, 3025\u20133027 (2003).","journal-title":"Blood"},{"key":"1141_CR138","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/JCO.2007.11.9214","volume":"26","author":"EM Sloand","year":"2008","unstructured":"Sloand, E. M., Wu, C. O., Greenberg, P., Young, N. & Barrett, J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J. Clin. Oncol. 26, 2505\u20132511 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR139","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley, D. M. et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N. Engl. J. Med. 376, 1540\u20131550 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR140","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3343\/alm.2022.42.3.299","volume":"42","author":"AG Jain","year":"2022","unstructured":"Jain, A. G., Zhang, L., Bennett, J. M. & Komrokji, R. Myelodysplastic syndromes with bone marrow fibrosis: an update. Ann. Lab. Med. 42, 299\u2013305 (2022).","journal-title":"Ann. Lab. Med."},{"key":"1141_CR141","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1200\/JCO.2008.18.2246","volume":"27","author":"MG Della Porta","year":"2009","unstructured":"Della Porta, M. G. et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J. Clin. Oncol. 27, 754\u2013762 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR142","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3324\/haematol.2010.031229","volume":"96","author":"N Kr\u00f6ger","year":"2011","unstructured":"Kr\u00f6ger, N. et al. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica 96, 291\u2013297 (2011).","journal-title":"Haematologica"},{"key":"1141_CR143","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.clml.2020.01.003","volume":"20","author":"M Melody","year":"2020","unstructured":"Melody, M. et al. Decoding bone marrow fibrosis in myelodysplastic syndromes. Clin. Lymphoma Myeloma Leuk. 20, 324\u2013328 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1141_CR144","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/modpathol.2013.187","volume":"27","author":"B Fu","year":"2014","unstructured":"Fu, B. et al. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod. Pathol. 27, 681\u2013689 (2014).","journal-title":"Mod. Pathol."},{"key":"1141_CR145","doi-asserted-by":"publisher","first-page":"e862","DOI":"10.1016\/S2352-3026(24)00251-5","volume":"11","author":"RS Komrokji","year":"2024","unstructured":"Komrokji, R. S. et al. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. Lancet Haematol. 11, e862\u2013e872 (2024).","journal-title":"Lancet Haematol."},{"key":"1141_CR146","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg, P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079\u20132088 (1997).","journal-title":"Blood"},{"key":"1141_CR147","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg, P. L. et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454\u20132465 (2012).","journal-title":"Blood"},{"key":"1141_CR148","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/leu.2017.33","volume":"31","author":"AM Zeidan","year":"2017","unstructured":"Zeidan, A. M. et al. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 31, 1391\u20131397 (2017).","journal-title":"Leukemia"},{"key":"1141_CR149","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1182\/blood-2024-208034","volume":"144","author":"B Rolles","year":"2024","unstructured":"Rolles, B. et al. Impact of response to hypomethylating agent-based therapy on survival outcomes in the context of baseline clinical-molecular risk and transplant status in patients with myelodysplastic syndromes\/neoplasms (MDS): an analysis from the International Consortium for MDS (icMDS) Validate Database. Blood 144, 664\u2013664 (2024).","journal-title":"Blood"},{"key":"1141_CR150","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/his.15353","volume":"86","author":"MG Della Porta","year":"2025","unstructured":"Della Porta, M. G., Bewersdorf, J. P., Wang, Y. H. & Hasserjian, R. P. Future directions in myelodysplastic syndromes\/neoplasms and acute myeloid leukaemia classification: from blast counts to biology. Histopathology 86, 158\u2013170 (2025).","journal-title":"Histopathology"},{"key":"1141_CR151","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","volume":"16","author":"W Bahaj","year":"2023","unstructured":"Bahaj, W. et al. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia. J. Hematol. Oncol. 16, 91 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"1141_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01290-0","volume":"15","author":"MV Shah","year":"2025","unstructured":"Shah, M. V. et al. Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer J. 15, 88 (2025).","journal-title":"Blood Cancer J."},{"key":"1141_CR153","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/bloodadvances.2024015238","volume":"9","author":"MV Shah","year":"2025","unstructured":"Shah, M. V. et al. Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Adv. 9, 3370\u20133380 (2025).","journal-title":"Blood Adv."},{"key":"1141_CR154","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1182\/bloodadvances.2024014499","volume":"9","author":"K Lontos","year":"2025","unstructured":"Lontos, K. et al. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS\/AML for transplantation. Blood Adv. 9, 2845\u20132854 (2025).","journal-title":"Blood Adv."},{"key":"1141_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101301","volume":"73","author":"A Mina","year":"2025","unstructured":"Mina, A., Madanat, Y., Abaza, Y. & Zeidan, A. M. Navigating the dynamic landscape of lower-risk MDS: advances and emerging insights. Blood Rev. 73, 101301 (2025).","journal-title":"Blood Rev."},{"key":"1141_CR156","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/S0145-2126(07)70197-2","volume":"31","author":"M Sekeres","year":"2007","unstructured":"Sekeres, M. et al. P127 Prospective cross-sectional analysis of cytopenias and transfusion needs of MDS patients in the USA. Leuk. Res. 31, S108\u2013S109 (2007).","journal-title":"Leuk. Res."},{"key":"1141_CR157","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1182\/blood.V128.22.5543.5543","volume":"128","author":"S Chuncharunee","year":"2016","unstructured":"Chuncharunee, S. et al. A prospective multicenter open-label study of the effectiveness of epoetin beta for patients with low\/intermediate-1-risk myelodysplastic syndrome (MDS): a preliminary result. Blood 128, 5543 (2016).","journal-title":"Blood"},{"key":"1141_CR158","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/leu.2017.192","volume":"31","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker, U. et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia 31, 1944\u20131950 (2017).","journal-title":"Leukemia"},{"key":"1141_CR159","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","volume":"32","author":"P Fenaux","year":"2018","unstructured":"Fenaux, P. et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-\u03b1 in anemic patients with low-risk MDS. Leukemia 32, 2648\u20132658 (2018).","journal-title":"Leukemia"},{"key":"1141_CR160","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson, B. D. et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108, 419\u2013425 (2006).","journal-title":"Blood"},{"key":"1141_CR161","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/bjh.20126","volume":"207","author":"V Santini","year":"2025","unstructured":"Santini, V. & Consagra, A. How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome. Br. J. Haematol. 207, 15\u201326 (2025).","journal-title":"Br. J. Haematol."},{"key":"1141_CR162","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/sj.leu.2403806","volume":"19","author":"P Bernasconi","year":"2005","unstructured":"Bernasconi, P. et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 19, 1424\u20131431 (2005).","journal-title":"Leukemia"},{"key":"1141_CR163","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/sj.leu.2403189","volume":"18","author":"AA Giagounidis","year":"2004","unstructured":"Giagounidis, A. A. et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18, 113\u2013119 (2004).","journal-title":"Leukemia"},{"key":"1141_CR164","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood.2025028619","volume":"146","author":"M Roncador","year":"2025","unstructured":"Roncador, M. et al. A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery. Blood 146, 1883\u20131896 (2025).","journal-title":"Blood"},{"key":"1141_CR165","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","volume":"111","author":"A Raza","year":"2008","unstructured":"Raza, A. et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111, 86\u201393 (2008).","journal-title":"Blood"},{"key":"1141_CR166","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa041668","volume":"352","author":"A List","year":"2005","unstructured":"List, A. et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352, 549\u2013557 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR167","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A List","year":"2006","unstructured":"List, A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456\u20131465 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR168","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","volume":"118","author":"P Fenaux","year":"2011","unstructured":"Fenaux, P. et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118, 3765\u20133776 (2011).","journal-title":"Blood"},{"key":"1141_CR169","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.41","volume":"8","author":"F Vinchi","year":"2024","unstructured":"Vinchi, F. & Platzbecker, U. Luspatercept: a peaceful revolution in the standard of care for myelodysplastic neoplasms. Hemasphere 8, e41 (2024).","journal-title":"Hemasphere"},{"key":"1141_CR170","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","volume":"18","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker, U. et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 18, 1338\u20131347 (2017).","journal-title":"Lancet Oncol."},{"key":"1141_CR171","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1182\/blood.2022016171","volume":"140","author":"AM Zeidan","year":"2022","unstructured":"Zeidan, A. M. et al. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood 140, 2170\u20132174 (2022).","journal-title":"Blood"},{"key":"1141_CR172","unstructured":"Bristol Myers Squibb BM. U.S. FDA approves Bristol Myers Squibb\u2019s Reblozyl\u00ae (Luspatercept-aamt) as First-line Treatment of Anemia in Adults with Lower-risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions https:\/\/news.bms.com\/news\/details\/2023\/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Reblozyl-luspatercept-aamt-as-First-Line-Treatment-of-Anemia-in-Adults-with-Lower-Risk-Myelodysplastic-Syndromes-MDS-Who-May-Require-Transfusions\/default.aspx (2023)."},{"key":"1141_CR173","unstructured":"(EMA) EMA. Reblozyl. Vol. 2025."},{"key":"1141_CR174","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/blood-2023-181237","volume":"142","author":"RS Komrokji","year":"2023","unstructured":"Komrokji, R. S. et al. Efficacy of imetelstat in achieving red blood cell transfusion independence (RBC-TI) across different risk subgroups in patients with lower-risk myelodysplastic syndromes (LR-MDS) relapsed\/refractory (R\/R) to erythropoiesis-stimulating agents (ESAs) in IMerge phase 3 study. Blood 142, 194 (2023).","journal-title":"Blood"},{"key":"1141_CR175","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56642-1","volume":"10","author":"BH Lee","year":"2020","unstructured":"Lee, B. H. et al. Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study. Sci. Rep. 10, 39 (2020).","journal-title":"Sci. Rep."},{"key":"1141_CR176","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1200\/JCO.2012.44.6823","volume":"31","author":"G Garcia-Manero","year":"2013","unstructured":"Garcia-Manero, G. et al. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J. Clin. Oncol. 31, 2548\u20132553 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR177","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","volume":"29","author":"G Garcia-Manero","year":"2011","unstructured":"Garcia-Manero, G. et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J. Clin. Oncol. 29, 2521\u20132527 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR178","doi-asserted-by":"publisher","first-page":"EVIDoa2200034","DOI":"10.1056\/EVIDoa2200034","volume":"1","author":"K Sasaki","year":"2022","unstructured":"Sasaki, K. et al. Low-dose decitabine versus low-dose azacitidine in lower-risk MDS. NEJM Evid. 1, EVIDoa2200034 (2022).","journal-title":"NEJM Evid."},{"key":"1141_CR179","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/MOH.0000000000000016","volume":"21","author":"AM Zeidan","year":"2014","unstructured":"Zeidan, A. M., Kharfan-Dabaja, M. A. & Komrokji, R. S. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Curr. Opin. Hematol. 21, 123\u2013130 (2014).","journal-title":"Curr. Opin. Hematol."},{"key":"1141_CR180","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","volume":"11","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas, E. et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 11, 3604\u20133608 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1141_CR181","unstructured":"Administration USFaD. Drug Approval Summary. Vol. 2026.; 2025."},{"key":"1141_CR182","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.leukres.2012.01.006","volume":"36","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker, U., Hofbauer, L. C., Ehninger, G. & H\u00f6lig, K. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk. Res. 36, 525\u2013536 (2012).","journal-title":"Leuk. Res."},{"key":"1141_CR183","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41375-018-0089-x","volume":"32","author":"R Stauder","year":"2018","unstructured":"Stauder, R. et al. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia 32, 1380\u20131392 (2018).","journal-title":"Leukemia"},{"key":"1141_CR184","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3324\/haematol.2018.212217","volume":"105","author":"L de Swart","year":"2020","unstructured":"de Swart, L. et al. Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. Haematologica 105, 632\u2013639 (2020).","journal-title":"Haematologica"},{"key":"1141_CR185","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000445163","volume":"136","author":"S Harnan","year":"2016","unstructured":"Harnan, S. et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis. Acta Haematol. 136, 23\u201342 (2016).","journal-title":"Acta Haematol."},{"key":"1141_CR186","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1016\/S2352-3026(24)00142-X","volume":"11","author":"M D\u00edez-Campelo","year":"2024","unstructured":"D\u00edez-Campelo, M. et al. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial. Lancet Haematol. 11, e659\u2013e670 (2024).","journal-title":"Lancet Haematol."},{"key":"1141_CR187","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1182\/blood-2023-178635","volume":"142","author":"AM Zeidan","year":"2023","unstructured":"Zeidan, A. M. et al. The ELEMENT-MDS Trial: a phase 3 randomized study evaluating luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, non-transfusion-dependent, lower-risk myelodysplastic syndromes. Blood 142, 6503\u20136503 (2023).","journal-title":"Blood"},{"key":"1141_CR188","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1182\/blood-2024-204791","volume":"144","author":"L Ades","year":"2024","unstructured":"Ades, L. et al. Combining ESA and luspatercept in non-RS MDS patients having failed ESA - Results of the phase 1-2 part a of the GFM Combola study. Blood 144, 351 (2024).","journal-title":"Blood"},{"key":"1141_CR189","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.26397","volume":"97","author":"DH Henry","year":"2022","unstructured":"Henry, D. H. et al. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: open-label, dose-selection, lead-in stage of a phase 3 study. Am. J. Hematol. 97, 174\u2013184 (2022).","journal-title":"Am. J. Hematol."},{"key":"1141_CR190","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/ajh.27410","volume":"99","author":"M Mittelman","year":"2024","unstructured":"Mittelman, M. et al. Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial. Am. J. Hematol. 99, 1778\u20131789 (2024).","journal-title":"Am. J. Hematol."},{"key":"1141_CR191","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1182\/blood-2024-206096","volume":"144","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero, G. et al. R289, a dual Irak 1\/4 inhibitor, in patients with relapsed\/refractory (R\/R) lower-risk myelodysplastic syndrome (LR-MDS): initial results from a phase 1b study. Blood 144, 4595 (2024).","journal-title":"Blood"},{"key":"1141_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54290-2","volume":"15","author":"JJ Rodriguez-Sevilla","year":"2024","unstructured":"Rodriguez-Sevilla, J. J. et al. The IL-1\u03b2 inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial. Nat. Commun. 15, 9840 (2024).","journal-title":"Nat. Commun."},{"key":"1141_CR193","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/blood-2024-198326","volume":"144","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero, G. et al. Preliminary safety and biomarker results of the NLRP3 inflammasome inhibitor DFV890 in adult patients with myeloid diseases: a phase 1b study. Blood 144, 353 (2024).","journal-title":"Blood"},{"key":"1141_CR194","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1182\/blood-2024-203073","volume":"144","author":"AM Zeidan","year":"2024","unstructured":"Zeidan, A. M. et al. A phase 2B, open-label multicenter study of tebapivat (AG-946), a potent pyruvate kinase activator, in patients with anemia due to lower-risk myelodysplastic syndromes. Blood 144, 6708 (2024).","journal-title":"Blood"},{"key":"1141_CR195","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman, L. R. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J. Clin. Oncol. 20, 2429\u20132440 (2002).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR196","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","volume":"117","author":"R Itzykson","year":"2011","unstructured":"Itzykson, R. et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117, 403\u2013411 (2011).","journal-title":"Blood"},{"key":"1141_CR197","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/leu.2015.283","volume":"30","author":"AM Zeidan","year":"2016","unstructured":"Zeidan, A. M. et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia 30, 649\u2013657 (2016).","journal-title":"Leukemia"},{"key":"1141_CR198","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.leukres.2014.03.004","volume":"38","author":"R Garc\u00eda-Delgado","year":"2014","unstructured":"Garc\u00eda-Delgado, R. et al. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leuk. Res. 38, 744\u2013750 (2014).","journal-title":"Leuk. Res."},{"key":"1141_CR199","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.2019004143","volume":"136","author":"G Garcia-Manero","year":"2020","unstructured":"Garcia-Manero, G. et al. Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study. Blood 136, 674\u2013683 (2020).","journal-title":"Blood"},{"key":"1141_CR200","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.bbmt.2017.03.020","volume":"23","author":"BM Getta","year":"2017","unstructured":"Getta, B. M. et al. Allogeneic hematopoietic stem cell transplantation is underutilized in older patients with myelodysplastic syndromes. Biol. Blood Marrow Transpl. 23, 1078\u20131086 (2017).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1141_CR201","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11899-013-0195-9","volume":"9","author":"E Atallah","year":"2014","unstructured":"Atallah, E., Bylow, K., Troy, J. & Saber, W. Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). Curr. Hematol. Malig. Rep. 9, 57\u201365 (2014).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"1141_CR202","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.3390\/cancers14102459","volume":"14","author":"M Leisch","year":"2022","unstructured":"Leisch, M. et al. Adverse events in 1406 patients receiving 13,780 cycles of azacitidine within the austrian registry of hypomethylating agents \u2014 a prospective cohort study of the AGMT study-group. Cancers 14, 2459 (2022).","journal-title":"Cancers"},{"key":"1141_CR203","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011860","volume":"97","author":"C Gao","year":"2018","unstructured":"Gao, C. et al. Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: a systematic review and meta-analysis. Medicine 97, e11860 (2018).","journal-title":"Medicine"},{"key":"1141_CR204","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR205","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1182\/blood.2024025464","volume":"145","author":"JS Garcia","year":"2025","unstructured":"Garcia, J. S. et al. Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood 145, 1126\u20131135 (2025).","journal-title":"Blood"},{"key":"1141_CR206","doi-asserted-by":"publisher","first-page":"TPS7054","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7054","volume":"39","author":"A Zeidan","year":"2021","unstructured":"Zeidan, A. et al. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk myelodysplastic syndromes. J. Clin. Oncol. 39, TPS7054 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR207","doi-asserted-by":"publisher","first-page":"S644","DOI":"10.1016\/S2152-2650(25)02083-X","volume":"25","author":"G Garcia-Manero","year":"2025","unstructured":"Garcia-Manero, G. et al. MDS-1497: primary analysis of the randomized, phase 3 VERONA study of venetoclax with azacitidine versus placebo with azacitidine in patients with treatment-na\u00efve, intermediate and higher-risk myelodysplastic syndromes. Clin. Lymphoma Myeloma Leukemia 25, S644\u2013S645 (2025).","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"1141_CR208","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/leu.2016.275","volume":"31","author":"BC Medeiros","year":"2017","unstructured":"Medeiros, B. C. et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia 31, 272\u2013281 (2017).","journal-title":"Leukemia"},{"key":"1141_CR209","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1182\/bloodadvances.2023012302","volume":"8","author":"CD DiNardo","year":"2024","unstructured":"DiNardo, C. D. et al. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome. Blood Adv. 8, 4209\u20134220 (2024).","journal-title":"Blood Adv."},{"key":"1141_CR210","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard, E. et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat. Med. 26, 1549\u20131556 (2020).","journal-title":"Nat. Med."},{"key":"1141_CR211","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","volume":"38","author":"C Bally","year":"2014","unstructured":"Bally, C. et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk. Res. 38, 751\u2013755 (2014).","journal-title":"Leuk. Res."},{"key":"1141_CR212","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.22.01794","volume":"41","author":"DA Sallman","year":"2023","unstructured":"Sallman, D. A. et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study. J. Clin. Oncol. 41, 2815\u20132826 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR213","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman, D. A. et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J. Clin. Oncol. 39, 1584\u20131594 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR214","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","volume":"6","author":"L Ad\u00e8s","year":"2022","unstructured":"Ad\u00e8s, L. et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 6, 5132\u20135145 (2022).","journal-title":"Blood Adv."},{"key":"1141_CR215","doi-asserted-by":"publisher","DOI":"10.1177\/20406207251347344","volume":"16","author":"JP Bewersdorf","year":"2025","unstructured":"Bewersdorf, J. P. et al. Integrated immune landscape analysis of RNA splicing factor-mutant AML and higher risk MDS treated with azacitidine \u00b1 durvalumab. Ther. Adv. Hematol. 16, 20406207251347344 (2025).","journal-title":"Ther. Adv. Hematol."},{"key":"1141_CR216","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","volume":"6","author":"AM Zeidan","year":"2022","unstructured":"Zeidan, A. M. et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Adv. 6, 2207\u20132218 (2022).","journal-title":"Blood Adv."},{"key":"1141_CR217","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00277-024-06081-4","volume":"104","author":"G Garcia-Manero","year":"2025","unstructured":"Garcia-Manero, G. et al. A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome. Ann. Hematol. 104, 1577\u20131585 (2025).","journal-title":"Ann. Hematol."},{"key":"1141_CR218","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100709","volume":"45","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf, J. P., Shallis, R. M. & Zeidan, A. M. Immune checkpoint inhibition in myeloid malignancies: moving beyond the PD-1\/PD-L1 and CTLA-4 pathways. Blood Rev. 45, 100709 (2020).","journal-title":"Blood Rev."},{"key":"1141_CR219","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00277-023-05552-4","volume":"103","author":"JP Bewersdorf","year":"2024","unstructured":"Bewersdorf, J. P. et al. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes\/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Ann. Hematol. 103, 105\u2013116 (2024).","journal-title":"Ann. Hematol."},{"key":"1141_CR220","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241257904","volume":"15","author":"AM Zeidan","year":"2024","unstructured":"Zeidan, A. M. et al. Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine. Therapeutic Adv. Hematol. 15, 20406207241257904 (2024).","journal-title":"Therapeutic Adv. Hematol."},{"key":"1141_CR221","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","volume":"11","author":"AM Zeidan","year":"2024","unstructured":"Zeidan, A. M. et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 11, e38\u2013e50 (2024).","journal-title":"Lancet Haematol."},{"key":"1141_CR222","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s11864-024-01264-7","volume":"25","author":"JM Watts","year":"2024","unstructured":"Watts, J. M., Shaw, S. J. & Jonas, B. A. Looking beyond the surface: olutasidenib and ivosidenib for treatment of mIDH1 acute myeloid leukemia. Curr. Treat. Options Oncol. 25, 1345\u20131353 (2024).","journal-title":"Curr. Treat. Options Oncol."},{"key":"1141_CR223","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.1182\/bloodadvances.2025016718","volume":"9","author":"JE Cortes","year":"2025","unstructured":"Cortes, J. E. et al. Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome. Blood Adv. 9, 5293\u20135305 (2025).","journal-title":"Blood Adv."},{"key":"1141_CR224","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","volume":"7","author":"EM Stein","year":"2020","unstructured":"Stein, E. M. et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 7, e309\u2013e319 (2020).","journal-title":"Lancet Haematol."},{"key":"1141_CR225","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","volume":"7","author":"CD DiNardo","year":"2023","unstructured":"DiNardo, C. D. et al. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. 7, 2378\u20132387 (2023).","journal-title":"Blood Adv."},{"key":"1141_CR226","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1182\/blood-2024-201317","volume":"144","author":"M Sebert","year":"2024","unstructured":"Sebert, M. et al. Enasidenib (ENA) monotherapy in patients with IDH2 mutated myelodysplastic syndrome (MDS), the ideal phase 2 study by the GFM and Emsco Groups. Blood 144, 1839 (2024).","journal-title":"Blood"},{"key":"1141_CR227","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Pr\u00e9bet","year":"2011","unstructured":"Pr\u00e9bet, T. et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J. Clin. Oncol. 29, 3322\u20133327 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR228","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1200\/JCO.20.02724","volume":"39","author":"N Kr\u00f6ger","year":"2021","unstructured":"Kr\u00f6ger, N. et al. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study). J. Clin. Oncol. 39, 3318\u20133327 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR229","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1200\/JCO.23.00866","volume":"41","author":"J Versluis","year":"2023","unstructured":"Versluis, J. et al. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study. J. Clin. Oncol. 41, 4497\u20134510 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR230","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1200\/JCO.2025.43.16_suppl.6567","volume":"43","author":"A Bazinet","year":"2025","unstructured":"Bazinet, A. et al. Allogeneic stem cell transplantation-related outcomes in myelodysplastic syndromes. J. Clin. Oncol. 43, 6567 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR231","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","volume":"28","author":"BL McClune","year":"2010","unstructured":"McClune, B. L. et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J. Clin. Oncol. 28, 1878\u20131887 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR232","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","volume":"28","author":"Z Lim","year":"2010","unstructured":"Lim, Z. et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J. Clin. Oncol. 28, 405\u2013411 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR233","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1182\/blood.2023023005","volume":"143","author":"A Mina","year":"2024","unstructured":"Mina, A., Greenberg, P. L. & Deeg, H. J. How I reduce and treat posttransplant relapse of MDS. Blood 143, 1344\u20131354 (2024).","journal-title":"Blood"},{"key":"1141_CR234","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","volume":"104","author":"CS Cutler","year":"2004","unstructured":"Cutler, C. S. et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104, 579\u2013585 (2004).","journal-title":"Blood"},{"key":"1141_CR235","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","volume":"31","author":"J Koreth","year":"2013","unstructured":"Koreth, J. et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J. Clin. Oncol. 31, 2662\u20132670 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR236","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ajh.23458","volume":"88","author":"EP Alessandrino","year":"2013","unstructured":"Alessandrino, E. P. et al. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am. J. Hematol. 88, 581\u2013588 (2013).","journal-title":"Am. J. Hematol."},{"key":"1141_CR237","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1038\/leu.2017.88","volume":"31","author":"MG Della Porta","year":"2017","unstructured":"Della Porta, M. G. et al. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia 31, 2449\u20132457 (2017).","journal-title":"Leukemia"},{"key":"1141_CR238","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/blood.2023022273","volume":"144","author":"C Scheid","year":"2024","unstructured":"Scheid, C. et al. Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms? Blood 144, 445\u2013456 (2024).","journal-title":"Blood"},{"key":"1141_CR239","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00744-z","volume":"12","author":"RS Komrokji","year":"2022","unstructured":"Komrokji, R. S. et al. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood Cancer J. 12, 148 (2022).","journal-title":"Blood Cancer J."},{"key":"1141_CR240","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","volume":"129","author":"T de Witte","year":"2017","unstructured":"de Witte, T. et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood 129, 1753\u20131762 (2017).","journal-title":"Blood"},{"key":"1141_CR241","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","volume":"5","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann, N. et al. Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis. JAMA Oncol. 5, 1739\u20131748 (2019).","journal-title":"JAMA Oncol."},{"key":"1141_CR242","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/bloodadvances.2023012385","volume":"8","author":"WB Fingrut","year":"2024","unstructured":"Fingrut, W. B. et al. Racial\/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation. Blood Adv. 8, 2753\u20132764 (2024).","journal-title":"Blood Adv."},{"key":"1141_CR243","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.bbmt.2019.10.012","volume":"26","author":"C Anthias","year":"2020","unstructured":"Anthias, C. et al. Role of race\/ethnicity in donor decisions about unrelated hematopoietic progenitor cell donation: exploring reasons for higher attrition among racial\/ethnic minorities. Biol. Blood Marrow Transpl. 26, 593\u2013599 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1141_CR244","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamaoncol.2021.6846","volume":"8","author":"GS Guru Murthy","year":"2022","unstructured":"Guru Murthy, G. S. et al. Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors. JAMA Oncol. 8, 404\u2013411 (2022).","journal-title":"JAMA Oncol."},{"key":"1141_CR245","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1182\/bloodadvances.2024013853","volume":"8","author":"RS Mehta","year":"2024","unstructured":"Mehta, R. S. et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 8, 5306\u20135314 (2024).","journal-title":"Blood Adv."},{"key":"1141_CR246","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott, B. L. et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J. Clin. Oncol. 35, 1154\u20131161 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR247","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","volume":"35","author":"N Kr\u00f6ger","year":"2017","unstructured":"Kr\u00f6ger, N. et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC Trial). J. Clin. Oncol. 35, 2157\u20132164 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR248","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley, R. C. et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N. Engl. J. Med. 376, 536\u2013547 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR249","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","volume":"32","author":"R Bejar","year":"2014","unstructured":"Bejar, R. et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J. Clin. Oncol. 32, 2691\u20132698 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR250","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","volume":"129","author":"T Yoshizato","year":"2017","unstructured":"Yoshizato, T. et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood 129, 2347\u20132358 (2017).","journal-title":"Blood"},{"key":"1141_CR251","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1080\/10428194.2025.2514662","volume":"66","author":"K Rathje","year":"2025","unstructured":"Rathje, K. & Kr\u00f6ger, N. Optimal timing of allogeneic hematopoietic stem cell transplant in MDS. Leuk. Lymphoma 66, 1788\u20131800 (2025).","journal-title":"Leuk. Lymphoma"},{"key":"1141_CR252","doi-asserted-by":"publisher","first-page":"e994","DOI":"10.1016\/S2352-3026(23)00265-X","volume":"10","author":"C Gurnari","year":"2023","unstructured":"Gurnari, C. et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 10, e994\u2013e1005 (2023).","journal-title":"Lancet Haematol."},{"key":"1141_CR253","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","volume":"4","author":"B Oran","year":"2020","unstructured":"Oran, B. et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 4, 5580\u20135588 (2020).","journal-title":"Blood Adv."},{"key":"1141_CR254","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","volume":"8","author":"JS Garcia","year":"2024","unstructured":"Garcia, J. S. et al. Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 8, 978\u2013990 (2024).","journal-title":"Blood Adv."},{"key":"1141_CR255","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1200\/JCO.22.00181","volume":"40","author":"A Mishra","year":"2022","unstructured":"Mishra, A. et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J. Clin. Oncol. 40, 3985\u20133993 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR256","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg0488","volume":"9","author":"TM Robinson","year":"2023","unstructured":"Robinson, T. M. et al. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Sci. Adv. 9, eadg0488 (2023).","journal-title":"Sci. Adv."},{"key":"1141_CR257","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1182\/bloodadvances.2023010098","volume":"7","author":"E Schulz","year":"2023","unstructured":"Schulz, E., Aplan, P. D., Freeman, S. D. & Pavletic, S. Z. Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes. Blood Adv. 7, 4381\u20134394 (2023).","journal-title":"Blood Adv."},{"key":"1141_CR258","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser, M. et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138, 2753\u20132767 (2021).","journal-title":"Blood"},{"key":"1141_CR259","doi-asserted-by":"publisher","first-page":"S616","DOI":"10.1016\/S2152-2650(25)02032-4","volume":"25","author":"G Garcia-Manero","year":"2025","unstructured":"Garcia-Manero, G. et al. MDS-730: Overall survival (OS) and duration of red blood cell-transfusion independence (RBC-TI) for first-line erythropoiesis-stimulating agent (ESA)-naive patients with lower-risk myelodysplastic syndromes (LR-MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial. Clin. Lymphoma Myeloma Leukemia 25, S616 (2025).","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"1141_CR260","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.2025029727","volume":"147","author":"M Stahl","year":"2026","unstructured":"Stahl, M. & Zeidan, A. M. The conundrum of drug development in higher-risk MDS: Lessons learned from recently failed phase 3 clinical trials. Blood 147, 811\u2013820 (2026).","journal-title":"Blood"},{"key":"1141_CR261","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/bloodadvances.2024014865","volume":"9","author":"A Mina","year":"2025","unstructured":"Mina, A. et al. Advancing drug development in myelodysplastic syndromes. Blood Adv. 9, 1095\u20131104 (2025).","journal-title":"Blood Adv."},{"key":"1141_CR262","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1038\/s41375-022-01724-9","volume":"36","author":"AM Zeidan","year":"2022","unstructured":"Zeidan, A. M. et al. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 36, 2939\u20132946 (2022).","journal-title":"Leukemia"},{"key":"1141_CR263","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood.2023023717","volume":"145","author":"U Borate","year":"2025","unstructured":"Borate, U. et al. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood 145, 1369\u20131381 (2025).","journal-title":"Blood"},{"key":"1141_CR264","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101128","volume":"62","author":"M Stahl","year":"2023","unstructured":"Stahl, M. et al. Classification, risk stratification and response assessment in myelodysplastic syndromes\/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 62, 101128 (2023).","journal-title":"Blood Rev."},{"key":"1141_CR265","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100615","volume":"37","author":"F Aakash","year":"2024","unstructured":"Aakash, F. et al. Contemporary approach to the diagnosis and classification of myelodysplastic neoplasms\/syndromes \u2014 recommendations from the International Consortium for Myelodysplastic Neoplasms\/Syndromes (MDS [icMDS]). Mod. Pathol. 37, 100615 (2024).","journal-title":"Mod. Pathol."},{"key":"1141_CR266","doi-asserted-by":"publisher","first-page":"968","DOI":"10.5858\/arpa.2024-0322-RA","volume":"149","author":"Gisriel","year":"2025","unstructured":"Gisriel et al. Standardization of bone marrow reporting for myelodysplastic syndromes\/neoplasms on behalf of the international consortium for myelodysplastic syndromes\/neoplasms. Arch. Pathol. Lab. Med. 149, 968\u2013976 (2025).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1141_CR267","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1182\/blood.2022017717","volume":"145","author":"SS Sahoo","year":"2025","unstructured":"Sahoo, S. S., Erlacher, M. & Wlodarski, M. W. Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management. Blood 145, 475\u2013485 (2025).","journal-title":"Blood"},{"key":"1141_CR268","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/blood-2015-09-669937","volume":"127","author":"MW Wlodarski","year":"2016","unstructured":"Wlodarski, M. W. et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood 127, 1387\u20131397 (2016).","journal-title":"Blood"},{"key":"1141_CR269","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/hematology.2023000490","volume":"2023","author":"MR Niewisch","year":"2023","unstructured":"Niewisch, M. R., Beier, F. & Savage, S. A. Clinical manifestations of telomere biology disorders in adults. Hematology 2023, 563\u2013572 (2023).","journal-title":"Hematology"},{"key":"1141_CR270","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3324\/haematol.2017.167726","volume":"102","author":"R Kanagal-Shamanna","year":"2017","unstructured":"Kanagal-Shamanna, R. et al. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102, 1661\u20131670 (2017).","journal-title":"Haematologica"},{"key":"1141_CR271","doi-asserted-by":"publisher","first-page":"a003210","DOI":"10.1101\/mcs.a003210","volume":"5","author":"M Swaminathan","year":"2019","unstructured":"Swaminathan, M. et al. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb. Mol. Case Stud. 5, a003210 (2019).","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"1141_CR272","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canep.2015.12.005","volume":"40","author":"JN Poynter","year":"2016","unstructured":"Poynter, J. N. et al. Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. Cancer Epidemiol. 40, 134\u2013140 (2016).","journal-title":"Cancer Epidemiol."},{"key":"1141_CR273","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2024024756","volume":"144","author":"Z Xie","year":"2024","unstructured":"Xie, Z. et al. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 144, 2033\u20132044 (2024).","journal-title":"Blood"},{"key":"1141_CR274","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M Lubbert","year":"2011","unstructured":"Lubbert, M. et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J. Clin. Oncol. 29, 1987\u20131996 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR275","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","volume":"11","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero, G. et al. Oral decitabine\u2013cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 11, e15\u2013e26 (2024).","journal-title":"Lancet Haematol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01141-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01141-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01141-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:02:20Z","timestamp":1782302540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01141-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":275,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01141-2","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"10 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S. has acted as a consultant and\/or adviser of Boston Consulting, BMS, Dedham Group, GLG, GSK, Kura, Kymera, Novartis, Rigel, Sierra Oncology, Sobi and Syndax; has participated in CME activity for Clinical Care Options, Curis Oncology, Haymarket Media and Novartis; and is a member of the Medical Safety Monitoring Board of Keros Pharmaceuticals. A.M.Z. has acted as a consultant and\/or adviser of AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, Beigene, Boehringer-Ingelheim, Celgene\/BMS, Chiesi\/Cornerstone Biopharma, Daiichi Sankyo, Dr Reddy, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Orum, Otsuka, Pfizer, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Syros, Syndax, Servier, Takeda, Treadwell, Taiho, Vincerx and Zentalis. J.P.B. and A.M. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}